In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Effects of rehabilitation on endothelial function and its prognostic value on recurrent chest pain in patients with stable coronary artery disease.

Session Poster Session 7

Speaker Dejan Simonovic

Event : ESC Congress 2013

  • Topic : preventive cardiology
  • Sub-topic : Rehabilitation: Outcomes
  • Session type : Poster Session

Authors : D Simonovic (Nis,RS), M Deljanin Ilic (Nis,RS), S Ilic (Nis,RS), G Kocic (Nis,RS), R Pavlovic (Nis,RS)

Authors:
D. Simonovic1 , M. Deljanin Ilic1 , S. Ilic1 , G. Kocic2 , R. Pavlovic2 , 1Institute of Cardiology, Medical Faculty University of Nis, Niška Banja, Serbia - Nis - Serbia , 2Institute of Biochemistry, Medical Faculty University of Nis, Serbia - Nis - Serbia ,

Citation:
European Heart Journal ( 2013 ) 34 ( Abstract Supplement ), 1087

Objective: To evaluate the effects of cardiac rehabilitation on endothelial function parameters (nitric oxide - (NOx), asymmetric-dimethylarginine (ADMA) and advanced oxidative protein products (AOPP), and their prognostic significance on recurrent chest pain in patients (pts) with stable coronary artery disease (CAD).

Design and method: 40 pts with stable CAD (55.68±8.24 years, 37 men), admitted at residential rehabilitation center, were studied. All patients underwent a 3 weeks supervised comprehensive rehabilitation program. At baseline and after 3 weeks in all pts values of NOx, ADMA and AOPP were determined. Clinical long-term follow-up (18 months) was performed. All medical therapy was documented, and this analysis was focused on recurrent chest pain during follow up period.

Results: After 18 months there were no cardiovascular (CV) hard end points (CV death, MI or stroke), but 18 pts (45%) had episodes of typical anginal chest pain (AP group) and 22 pts (55%) were without (no-AP group). During rehabilitation NOx increased in both groups: in no-AP group (from 35.86±8.99 to 47.86±13.85 μmol/L, p < 0.0005) and in AP group (from 33.63±6.41 to 38.95±9.28 μmol/L, ns) with significantly higher second measurements in no-AP group (p = 0.016). ADMA levels were decreased in both groups: no-AP group (p = 0.011) and AP group (ns). AOPP also decreased in both groups: in no-AP group (from 321.96±27.92 to 294.96±13.84 μmol/L, p < 0.0005) and in AP group (from 300.21±17.46 to 284.13±52.95 μmol/L, ns). Univaried logistic regression analyses showed that only second NOx values are significantly connected to appearance of anginal chest pain (OR 0.931, CI 0.870 - 0.996, p = 0.037).

Conclusion: In pts with stable coronary artery disease 3 weeks of supervised rehabilitation program induced improvement in endothelial function. Patients without anginal chest pain during follow up period of 18 months, had higher increase of NOx, and greater reduction in ADMA and AOPP values after 3 weeks of rehabilitation. Among other endothelial parameters, NOx was proven to be an independent predictor of recurrent anginal chest pain.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are